Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
News Medical on MSN21h
HIV drug access remains a major challenge despite promising trial results
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
Dow tumbles nearly 700 points Friday as strong jobs report casts doubt over Fed's rate-cut path
The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...
securities23h
The Next Big Thing: MIT Technology Review Reveals Game-Changing Technologies
Technology is advancing at a rapid pace, transforming all areas of our lives and leaving barely any aspect of it unimpacted.  This is not a new phenomenon by any degree. Many centuries ago, the ...
Psychedelic drug developer Lykos could get lifeline from former Tesla board member
Former Tesla board member Antonio Gracias offers to rescue Lykos Therapeutics with $100M deal to save its psychedelic drug ...
The New York Times15h
New York Times - Top Stories
Supreme Court Seems Poised to Uphold Law That Could Ban TikTok The justices are expected to rule quickly in the case, which pits national security concerns about China against free speech ...